Received Jan 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
| FLU3 | INFLUENZA (SEASONAL) (FLUAD) | SEQIRUS, INC. | UNK | — | — |
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Arms are sore; alc elevated; This Spontaneous report was received from a 60-year-old Male patient reporting on himself. The patient's concomitant medication included methotrexate, tamsulosin hydrochloride, varenicline tartrate (CHANTIX), prednisone, colecalciferol (VITAMIN D3), and vitamins NOS. No information was provided regarding the patient's medical history, concurrent conditions and drug reactions or allergies. On an unknown date, patient started therapy with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) 25 mcg/0.5 syringe, COVID-19 vaccine, Varicella zoster vaccine rgE (CHO) (SHINGRIX) 50 mcg/0.5ml and Influenza vaccine inact sAg 3v (FLUAD) 45 mcg/0.5ml) all of them for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported). On an unknown date, the patient received the first dose of sarilumab (KEVZARA) strength: 200mg/1.14ml, at a dose of 200 mg, (QOW) every one week, subcutaneously. On an unknown date, the patient experienced a1c elevated (Glycosylated haemoglobin increased). and the arms were sore (Pain in extremity). The outcome of the events was not provided. The action taken with sarilumab (KEVZARA) was unknown. Causality assessment between the events and the suspect therapies was not provided. Lot # is being requested and will be submitted if received.
Methotrexate D; Tamsulosin hydrochloride; Chantix; Prednisone; Vitamin d3; VITAMINS NOS; KEVZARA